LIFR and neoplasm: LIFR expression (detected in 16 of 24 patients all of whom received neoCRT) was significantly reduced in tumour biopsies from patients having a subsequent poor pathological response to neoCRT (p<0.001), when compared to good responders (Figure 3C).